CICLESONIDE CONTAINING AQUEOUS PHARMACEUTICAL COMPOSITION
An aqueous pharmaceutical composition which comprises ciclesonide, crystalline cellulose carmellose sodium and hydroxypropylmethylcellulose is provided.
1 - 14 . (canceled)
15 . An aqueous pharmaceutical composition which comprises ciclesonide, crystalline cellulose carmellose sodium and hydroxypropylmethylcellulose, wherein said crystalline cellulose carmellose sodium concentration is 1.7% w/w, and wherein said hydroxypropylmethylcellulose concentration is from 0.1% w/w to 0.5% w/w, relative to the total amount of the composition.
16 . An aqueous pharmaceutical composition according to claim 15 , which further comprises one or more types of a water-insoluble substance and/or water-low soluble substance which is one or more types of cellulose.
17 . An aqueous pharmaceutical composition according to claim 16 , which further comprises a water-soluble polymer substance.
18 . An aqueous pharmaceutical composition according to claim 17 , wherein said water-soluble polymer substance is one or more types selected from the group consisting of polyethylene glycol, propylene glycol alginate, pectin, methoxyl pectin, guar gum, gum arabic, carrageenan, methylcellulose, xanthan gum and hydroxypropylcellulose.
19 . An aqueous pharmaceutical composition according to claim 17 , wherein said water-soluble polymer substance is polyethylene glycol.
20 . An aqueous pharmaceutical composition according to claim 17 , wherein said water-soluble polymer substance is hydroxypropylcellulose.
21 . An aqueous pharmaceutical composition according to claim 15 , which further comprises a water-soluble polymer substance.
22 . An aqueous pharmaceutical composition according to claim 21 , wherein said water-soluble polymer substance is one or more types selected from the group consisting of polyethylene glycol, propylene glycol alginate, pectin, methoxyl pectin, guar gum, gum arabic, carrageenan, methylcellulose, xanthan gum and hydroxypropylcellulose.
23 . An aqueous pharmaceutical composition according to claim 21 , wherein said water-soluble polymer substance is polyethylene glycol.
24 . An aqueous pharmaceutical composition according to claim 21 , wherein said water-soluble polymer substance is hydroxypropylcellulose.
25 . An aqueous pharmaceutical composition according to claim 15 , wherein the ciclesonide particles have a size of between about 10 nm and about 100 μm.
26 . An aqueous pharmaceutical composition according to claim 15 , wherein the ciclesonide particles have a size of between about 10 nm and about 10 μm.
27 . An aqueous pharmaceutical composition according to claim 15 , further comprising at least one wetting agent.
28 . An aqueous pharmaceutical composition according to claim 27 , wherein at least one wetting agent present is selected from the group consisting of Polysorbate 80, glycerin monostearate, polyoxyl stearate, lauromacrogol, sorbitan oleate and sucrose fatty acid esters.
29 . An aqueous pharmaceutical composition according to claim 15 , further comprising at least one osmotic-pressure controlling agent.
30 . An aqueous pharmaceutical composition according to claim 29 , wherein at least one osmotic-pressure controlling agent present is a salt.
31 . An aqueous pharmaceutical composition according to claim 30 , wherein the salt is sodium chloride.
32 . An aqueous pharmaceutical composition according to claim 29 , wherein at least one osmotic-pressure controlling agent present is a water-soluble sugar.
33 . An aqueous pharmaceutical composition according to claim 32 , wherein the water-soluble sugar is glucose.
34 . An aqueous pharmaceutical composition according to claim 15 , wherein the ciclesonide is present in a concentration of between about 0.01% w/w and about 1% w/w, relative to the total amount of the composition.
35 . An aqueous pharmaceutical composition according to claim 15 , wherein the ciclesonide is present in a concentration of between about 0.05% w/w and about 0.5% w/w, relative to the total amount of the composition.
36 . An aqueous pharmaceutical composition according to claim 15 , further comprising at least one antiseptic.
37 . An aqueous pharmaceutical composition according to claim 36 , wherein at least one antiseptic present is benzalkonium chloride.
38 . An aqueous pharmaceutical composition according to claim 15 , further comprising at least one pH controlling agent.
39 . An aqueous pharmaceutical composition according to claim 38 , wherein at least one pH controlling agent present is selected from the group consisting of hydrochloric acid and sodium hydroxide.
40 . An aqueous pharmaceutical composition according to claim 38 , wherein the at least one pH controlling agent is hydrochloric acid.
41 . An aqueous pharmaceutical composition according to claim 15 , further comprising at least one preservative.
42 . An aqueous pharmaceutical composition according to claim 41 , wherein at least one preservative present is ascorbic acid.
43 . An aqueous pharmaceutical composition according to claim 15 , further comprising at least one buffer.
44 . An aqueous pharmaceutical composition according to claim 43 , wherein at least one buffer present is selected from the group consisting of phosphoric acid and salts thereof.
45 . An aqueous pharmaceutical composition according to claim 15 , further comprising
(a) at least one pH controlling agent, and
(b) at least one antiseptic or at least one preservative.